BCG Vaccination strategy for prevention against COVID-19: Hype or Hope?

Keshav Rajarshi¹, Aroni Chatterjee² and Shashikant Ray³ *

¹School of Community Science and Technology (SOCSAT) Indian Institute of Engineering Science and Technology (IIEST), Shibpur, Howrah, West Bengal-711103, India
²Indian Council of Medical Research (ICMR)—Virus Research Laboratory, NICED, Kolkata, India
³Department of Biotechnology, Mahatma Gandhi Central University Motihari-845401, India

*Correspondence may be addressed to this author

³*. Shashikant Ray, Assistant Professor, Department of Biotechnology, Mahatma Gandhi Central University Motihari-845401, India, E-mail: shashikantray@mgcub.ac.in

Keywords: COVID-19, BCG immunization, SARS-CoV-2, Immunity and Tuberculosis
Abstract

The Bacillus Calmette-Guerin vaccine (BCG vaccine) designed to prevent tuberculosis in children has been shown to induce a trained immune response in the body to fight against bacteria as well as other parasites and viruses. This knowledge has been reciprocated to generate the idea that this vaccine can also offer protection against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Some recent pre-print articles have highlighted that countries with mass BCG immunizations seems to have a lower incidence of coronavirus disease 2019 (COVID-19) compared to those without BCG immunization. There are yet no experimental proof of any such association and the world health organisation (WHO) is currently testing the theory with clinical trials on selected cohorts. Epidemiologists and other scientific experts has expressed both their hope and concern simultaneously regarding the success theory of BCG vaccination to prevent COVID-19. Though its still not verified in any way whether the BCG vaccination can actually prevent COVID-19 or not but we believe a thorough analytical research in this regard is indeed worth a shot.

1. Introduction

The whole world, currently, is combating the COVID-19, which is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). It is posing a significant threat to global health as well as the economy. The medium of the spread of this novel virus is primarily through respiratory droplets, close and physical contact. With a non-uniform pattern of development, in its first three months, this novel virus has infected more than 3,00,000 individuals and caused more than 13,000 deaths (1). The figures keep on increasing.

SARS-CoV-2 belongs to Coronaviridae family, possessing a positive-sense single-stranded RNA genome (2-4). It is the seventh type of coronavirus to infect humans and cause ailments. The other six members of the coronaviridae family-like SARS-CoV or MERS-CoV (Middle East Respiratory Syndrome Coronavirus) are also known for their pathogenicity with comparatively higher mortality rate than that of SARS-CoV-2 (5).

Currently, not a single antiviral or antimicrobial treatment has been proven to be useful for COVID-19. Combining more than three antivirals are not recommended. At the moment, treatment options are primarily based on the previous encounters and results showing benefits in the treatment of SARS, Ebola, MERS influenza, and other viral infections (6).
1.1. **BCG vaccine and its antiviral role**

Bacillus Calmette-Guerin (BCG) vaccine is basically used for the treatment of tuberculosis (TB) and it was introduced in 1921. It is a live attenuated strain obtained from *Mycobacterium bovis* isolate. Relevant studies retrieved from PubMed and clinicaltrial.gov, suggested that some strains of BCG vaccine not only prevented the propagated types of TB, but also induced protection against infections with other non-mycobacterial pathogens or non-related causative agents (7). In case of humans, evidences obtained from laboratory and clinical experiments and studies suggests that BCG vaccination may have non-specific preventive results against viral infections (8). For example, in the BCG-vaccinated mice, enhanced production of interferon gamma (IFN-γ) from the CD4+ cells took place in order to prevent the infection from the vaccinia virus (9). This phenomenon of stimulation of CD4+ cells for overproduction of IFN-γ for prevention of viral infection was termed as ‘trained immunity’.

Various metabolic as well as epigenetic changes are responsible for causing trained immunity. Due to this trained immunity caused by these metabolic and epigenetic changes, various genetic regions are promoted for encoding of pro-inflammatory cytokines (10). Pro-inflammatory cytokines like Interleukin-1B (IL-1B), also known as leukocytic pyrogen have an enhance in their secretions on BCG vaccination. IL-1B is known to have a crucial role in immunity against viruses (11).

A study conducted in West-African country Guinea Bissau suggested that BCG vaccinated children experienced a reduction of 50% in overall mortality. It was inferred that this reduction in overall mortality was due to BCG vaccine which reduced sepsis and further, respiratory infections (12).

1.2. **Epidemiological studies**

Various epidemiological studies arrived at a similar conclusion that the countries which adopted the universal BCG vaccination policy had a reduced mortality rate (Table 1) due to COVID-19 compared to the countries which did not implement the policy (1, 13). It was hypothesised that protection offered by BCG vaccination against COVID-19 was due vaccine’s non-specific effects. These non-specific effects caused a reduction in respiratory tract infections in children, reduced viremia and antiviral effects in experimental animals (7).
1.3. BCG vaccine: non-specific effects

Since 1970s BCG vaccines are known to have non-specific immune effects. BCG showed improved immunity against influenza and listeria in murine models (14, 15). Recent studies exhibited the mechanism of BCG vaccine and its non specific effects at molecular level. These unspecific benefits of the vaccine are primarily due to NOD2 and mTOR arbitrated changes in the immune cell’s epigenetic landscape (10, 16-18).

There is a persistent change induced in the conformation of chromatin in adaptive and innate immune cells due to the BCG priming. These changes help the immune cells in improving immunity against bacterial, fungal, mycobacterial and viral infections (10, 16, 17, 19-22).

2. BCG vaccine: hope or hype?

BCG vaccinated healthcare workers involved in the care of patients suffering from COVID-19 were studied as subjects and clinical trials were run on them using two registered protocols which aimed at observing whether the vaccine was enhancing their immunity against SARS-CoV-2 (23, 24).

At present, due to the unavailability of any concrete evidences stating the fact that BCG vaccine prevents the infection of SARS-CoV-2, WHO does not approve of using the vaccine for treatment of COVID-19. Inspite the fact that studies and experiments conducted both on humans and animals have suggested the NSEs (non-specific effects) of BCG vaccine on immune system, the clinical relevance and proper classification of these effects are still not known. Epidemiological studies, that indicate less reported cases of COVID-19 in BCG vaccinated neonates, are influenced by various factors including the burden of disease and differences in demographics of the country, testing rates for COVID-19 virus infections and phase of the pandemic in each country.

3. Conclusion

Although BCG is known to possess the NSEs (non-specific effects) and also known to augment the immune system against viral infection, yet there are no strong clinical evidences suggesting that it might be a solution to cure COVID-19. WHO does not recommend the promotion of BCG vaccination for COVID-19 prevention, however WHO still continues to recommend BCG vaccination for newborns in areas with high occurrences of tuberculosis.
Further experimental work needs to be conducted for clarification of the fact whether BCG vaccine is a hype or a hope amidst the pandemic.

Acknowledgements

KR and SR thanks IIEST Shibpur and Mahatma Gandhi Central University Motihari, Bihar, respectively.

Disclosure statement

The authors report no conflicts of interest

| Abbreviations | Description |
|---------------|-------------|
| COVID-19      | Coronavirus Disease 2019 |
| SARS-CoV-2S   | Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein |
| BCG           | Bacille Calmette-Guérin |
| WHO           | World Health Organization |
| MERS-CoV      | Middle East Respiratory Syndrome coronavirus |
| NSEs          | Non-specific effects |
| IL-1B         | Interleukin-1B |
| IFN-γ         | Interferon gamma |
References

1. Hegarty P, Kamat A, Zafirakis H, & Dinardo A (2020) BCG vaccination may be protective against Covid-19.
2. Anonymous (2020) The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nature microbiology 5(4):536-544.
3. Fehr AR & Perlman S (2015) Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol 1282:1-23.
4. Jitendra Subhash R, Aroni C, Abhijeet K, & Shashikant R (2020) Targeting SARS-CoV-2 Spike Protein of COVID-19 with Naturally Occurring Phytochemicals: An in Silico Study for Drug Development.
5. Paules CI, Marston HD, & Fauci AS (2020) Coronavirus Infections—More Than Just the Common Cold. Jama.
6. Zhou M, Zhang X, & Qu J (2020) Coronavirus disease 2019 (COVID-19): a clinical update. Frontiers of medicine.
7. Moorlag S, Arts RJW, van Crevel R, & Netea MG (2019) Non-specific effects of BCG vaccine on viral infections. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 25(12):1473-1478.
8. Aaby P, et al. (2011) Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? The Journal of infectious diseases 204(2):245-252.
9. Mathurin KS, Martens GW, Kornfeld H, & Welsh RM (2009) CD4 T-cell-mediated heterologous immunity between mycobacteria and poxviruses. Journal of virology 83(8):3528-3539.
10. Netea MG, et al. (2016) Trained immunity: A program of innate immune memory in health and disease. Science 352(6284):aaf1098.
11. Kleinnijenhuis J, et al. (2014) Long-lasting effects of BCG vaccination on both heterologous Th1/Th17 responses and innate trained immunity. Journal of innate immunity 6(2):152-158.
12. Kristensen I, Aaby P, & Jensen H (2000) Routine vaccinations and child survival: follow up study in Guinea-Bissau, West Africa. BMJ 321(7274):1435-1438.
13. Miller A, et al. (2020) Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. medRxiv:2020.2003.2024.20042937.
14. Spencer JC, Ganguly R, & Waldman RH (1977) Nonspecific protection of mice against influenza virus infection by local or systemic immunization with Bacille Calmette-Guerin. The Journal of infectious diseases 136(2):171-175.
15. Ratzan KR, Musher DM, Keusch GT, & Weinstein L (1972) Correlation of increased metabolic activity, resistance to infection, enhanced phagocytosis, and inhibition of bacterial growth by macrophages from Listeria- and BCG-infected mice. *Infection and immunity* 5(4):499-504.

16. Arts RJW, et al. (2016) Immunometabolic Pathways in BCG-Induced Trained Immunity. *Cell reports* 17(10):2562-2571.

17. Kleinnijenhuis J, et al. (2012) Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. *Proceedings of the National Academy of Sciences of the United States of America* 109(43):17537-17542.

18. Netea MG (2013) Training innate immunity: the changing concept of immunological memory in innate host defence. *European journal of clinical investigation* 43(8):881-884.

19. Arts RJ, et al. (2015) Long-term in vitro and in vivo effects of gamma-irradiated BCG on innate and adaptive immunity. *Journal of leukocyte biology* 98(6):995-1001.

20. Arts RJW, et al. (2018) BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained Immunity. *Cell host & microbe* 23(1):89-100 e105.

21. Joosten SA, et al. (2018) Mycobacterial growth inhibition is associated with trained innate immunity. *The Journal of clinical investigation* 128(5):1837-1851.

22. Verma D, et al. (2017) Anti-mycobacterial activity correlates with altered DNA methylation pattern in immune cells from BCG-vaccinated subjects. *Scientific reports* 7(1):12305.

23. Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine (BCG-CORONA). [https://clinicaltrials.gov/ct2/show/NCT04328441](https://clinicaltrials.gov/ct2/show/NCT04328441).

24. BCG Vaccination to Protect Healthcare Workers Against COVID-19 (BRACE). [https://clinicaltrials.gov/ct2/show/NCT04327206](https://clinicaltrials.gov/ct2/show/NCT04327206).
Table 1.

|                               | Incidence (per million) | Death rate (per million) |
|-------------------------------|-------------------------|--------------------------|
| Countries with BCG vaccination policy. | 38.4                    | 4.28                     |
| Countries without BCG vaccination policy. | 358.4                   | 40                       |

Table 1: Depicting that countries with BCG vaccination policy have lower infection due to COVID-19 and mortality rates compared to those that do not have the policy.

Figure 1:

Figure 1: Global implementation of BCG vaccination policy. The pie chart was plotted based on study conducted in 178 countries (1) (A) % of countries with BCG vaccination policy (B) % of countries without BCG vaccination policy (C) Unclear whether they had this policy